Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HK2 | P52789 | 5/20 | 0.48 |
| ▸ | HK1 | P19367 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29142537 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL14620999 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL5160455 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL15966251 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL14653772 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL15966275 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL14520986 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL15965643 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL5158214 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL22166026 | 1.00 | PYGB (0.66) | PYGBKDM4ELMNACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320373-B1 | TREATMENT OF ARTHRITIS AND COMPOSITIONS THEREFORE | ANASTASSIADES TASSOS P (CA) | 2007-01-31 | — | — | EP | disclosed |
| EP-1320373-A2 | TREATMENT OF ARTHRITIS AND COMPOSITIONS THEREFORE | Anastassiades, Tassos, P. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6479469-B2 | N-ACYLATED-2-GLUCOSAMINE DERIVATIVES FOR TREATING OSTEOARTHRITIS/INFLAMMATORY ARTHRITIS, AND ENHANCING CARTILAGE FORMULATION, CHONDROCYTE CELL PROLIFERATION AND GLYCOSAMINOGLYCAN PRODUCTION | ANACOTI LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-20020045597-A1 | Treatment of arthritis and compositions therefore | ANACOTI LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| WO-2002017890-A2 | TREATMENT OF ARTHRITIS AND COMPOSITIONS THEREFORE CONTAINING A N-ACYLATED-2-GLUCOSAMINE DERIVATIVE | ANASTASSIADES TASSOS P (CA) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045597-A1 | Treatment of arthritis and compositions therefore | COL2A1, B3GNT2, CSGALNACT1 | PYGB 1521/4885KDM4E 2825/4885LMNA 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.